# The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

> **NCT03262727** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 49 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Arthritic Psoriasis
- Psoriasis
- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** BMS-986165
- **DRUG:** Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)

## Key facts

- **NCT ID:** NCT03262727
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2017-11-23
- **Final completion:** 2017-12-19
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03262727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03262727, "The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03262727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*